



## Panelist



**Christian S. Schade**  
**Executive Vice President and CFO**  
**Omthera Pharmaceuticals, Inc.**

Christian S. Schade was Executive Vice President and CFO of Omthera Pharmaceuticals, Inc., a NASDAQ listed Princeton-based emerging specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia. At Omthera Mr. Schade was responsible for all corporate finance, accounting and business development activities. In July 2013, AstraZeneca purchased Omthera for a total potential consideration of approximately \$445 million. From April 2010 to September 2011, Mr. Schade served as Executive Vice President and CFO at NRG Energy, a NYSE listed, S&P 500 wholesale power generation company based in Princeton. While there, he was responsible for NRG's corporate financial functions, including Treasury, Accounting, Tax, Risk, Credit Management and Insurance. Prior to joining NRG, he was Senior Vice President Administration and CFO at Medarex Inc., a NASDAQ listed, Princeton-based biopharmaceutical company which was acquired for \$2.4 billion by Bristol-Myers Squibb Co. in September 2009. Mr. Schade played a lead role in negotiations for the sale of Medarex to Bristol-Myers Squibb and helped lead the merger-integration process of the research, development and administrative functions. He also helped Medarex to grow to become a leading pharmaceutical development company, raising capital through a series of public capital market and asset monetization transactions. While there, he also oversaw the manufacturing of multiple development/clinical programs and was responsible for the business development team. Before joining Medarex in 2000, Mr. Schade served as Managing Director at Merrill Lynch in London, where he was head of the European Corporate Funding Group and was responsible for certain capital markets activities of Merrill Lynch's European corporate clients. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) and is Chair of the Board of Trustees at Princeton Academy School. Mr. Schade received an A.B. from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.